{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:31:26Z","timestamp":1778509886901,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jpba.2024.116160","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T21:58:10Z","timestamp":1713477490000},"page":"116160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeted and untargeted screening for impurities in losartan tablets marketed in Germany by means of liquid chromatography\/high resolution mass spectrometry"],"prefix":"10.1016","volume":"245","author":[{"given":"Laura","family":"Backer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Kinzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"S\u00f6rgel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Holzgrabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116160_bib1","unstructured":"Fachinformation: LosAmlo\u00ae Filmtabletten. \u3008https:\/\/www.tad.de\/media\/products\/de\/rx\/gen_pdf\/2018\/losamlo__alle_st_rken_filmtabletten_425304__38795__stand_februar_2017__ohne_legende_.pdf\u3009. Accessed February 29, 2024."},{"key":"10.1016\/j.jpba.2024.116160_bib2","unstructured":"Fachinformation: LORZAAR\u00aePLUS. \u3008https:\/\/www.organon.com\/germany\/wp-content\/uploads\/sites\/38\/2022\/08\/011464_54300_80610_1_DL_2022-08-02_LORZAAR-PLUS.pdf\u3009. Accessed February 29, 2024."},{"key":"10.1016\/j.jpba.2024.116160_bib3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0149-2918(96)80212-8","article-title":"Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension","volume":"18","author":"Oparil","year":"1996","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2024.116160_bib4","unstructured":"S3-Leitlinie Nationale VersorgungsLeitlinie Hypertonie 2023. \u3008https:\/\/register.awmf.org\/assets\/guidelines\/nvl-009k_S3_Hypertonie_2023-06.pdf\u3009. Accessed February 29, 2024."},{"key":"10.1016\/j.jpba.2024.116160_bib5","unstructured":"European Medicines Agency. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity. (July 5, 2018). \u3008https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity_en.pdf\u3009. Accessed February 29, 2024."},{"key":"10.1016\/j.jpba.2024.116160_bib6","unstructured":"European Medicines Agency: Valsartan. review of impurities extended to other sartan medicines. (September 21, 2018). \u3008https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/valsartan-review-impurities-extended-other-sartan-medicines_en.pdf\u3009. Accessed February 29, 2024."},{"key":"10.1016\/j.jpba.2024.116160_bib7","unstructured":"Xiaoren Z., Nianping S., Wenling Z., Peng W., Inventors; Zhejiang Huahai Pharm Co ltd, assignee. Improved method for preparing tetrazole for valsartan. CN 104045602\u2009A. September 17, 2014."},{"key":"10.1016\/j.jpba.2024.116160_bib8","unstructured":"Arzneimittelkommission der Deutschen Apotheker. Liste der (Chargen-)R\u00fcckrufe Sartan-haltiger Arzneimittel. \u3008https:\/\/www.abda.de\/fuer-apotheker\/arzneimittelkommission\/amk-nachrichten\/detail\/online-nachricht-amk-liste-der-chargen-rueckrufe-sartan-haltiger-arzneimittel\/\u3009. Accessed February 29, 2024."},{"key":"10.1016\/j.jpba.2024.116160_bib9","unstructured":"Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human. Azido impurity in irbesartan confirmed positive in bacterial mutagenicity test. (April 2021). \u3008https:\/\/www.dls.gov.ua\/wp-content\/uploads\/2021\/07\/\u3009\u0414\u043e\u0434\u0430\u0442\u043e\u043a-\u041b\u0438\u0441\u0442-CMDh_430_2021.pdf. Accessed February 29, 2024."},{"key":"10.1016\/j.jpba.2024.116160_bib10","unstructured":"Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human. Risk of azido-impurity in losartan-containing medicinal products. (September 23, 2021).\u3008https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/PSUSAS\/m-r\/octreotid_cmdh_Anlage-3.pdf?__blob=publicationFile\u3009. Accessed February 29, 2024."},{"key":"10.1016\/j.jpba.2024.116160_bib11","unstructured":"Holzgrabe U., Buschmann H. Wie \u201esauber\u201c sind Sartane? DAZ. 2021;41:60. https:\/\/www.deutsche-apotheker-zeitung.de\/daz-az\/2021\/daz-41-2021\/wie-sauber-sind-sartane#:\u223c:text=Spezifische%20Verunreinigungen%20der%20Sartane%20mit,in%20vielen%20Sartanen%20vorkommt%20(s. Accessed February 29, 2024."},{"key":"10.1016\/j.jpba.2024.116160_bib12","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/op300179u","article-title":"An efficient, commercially viable, and safe process for preparation of losartan potassium, an angiotensin II receptor antagonist","volume":"16","author":"Madasu","year":"2012","journal-title":"Org. Process Res Dev."},{"key":"10.1016\/j.jpba.2024.116160_bib13","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1021\/jm00112a031","article-title":"Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl) imidazoles as potent, orally active antihypertensives","volume":"34","author":"Carini","year":"1991","journal-title":"J. Med Chem."},{"key":"10.1016\/j.jpba.2024.116160_bib14","unstructured":"Reddy A.V. , Inventor; Suven Life Sciences Limited, assignee. Process for the preparation of losartan. US 2010\/0222597 A1. September 2, 2010."},{"key":"10.1016\/j.jpba.2024.116160_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3184\/174751915X14379907479622","article-title":"An efficient and green synthetic route to losartan","volume":"39","author":"Shuangxia","year":"2015","journal-title":"J. Chem. Res"},{"key":"10.1016\/j.jpba.2024.116160_bib16","unstructured":"Losartan potassium European Pharmacopoeia 11.0, text number 2232. Council of Europe, Strasbourg, France, 2022."},{"key":"10.1016\/j.jpba.2024.116160_bib17","unstructured":"Losartan potassium Japanese pharmacopoeia 18. Pharmaceuticals and Medical Devices Agency, Tokyo, Japan, 2021."},{"key":"10.1016\/j.jpba.2024.116160_bib18","unstructured":"Losartan potassium tablets USP43-NF 38. U.S. Food and Drug Administration, Silver Spring, Maryland, USA, 2020."},{"key":"10.1016\/j.jpba.2024.116160_bib19","unstructured":"Losartan potassium and hydrochlorothiazide tablets USP43-NF 38. U.S. Food and Drug Administration, Silver Spring, Maryland, USA, 2020."},{"key":"10.1016\/j.jpba.2024.116160_bib20","first-page":"1","article-title":"Charged aerosol detector response modeling for fatty acids based on experimental settings and molecular features: a machine learning approach","volume":"13","author":"Pawellek","year":"2021","journal-title":"Crit. Rev. Anal."},{"key":"10.1016\/j.jpba.2024.116160_bib21","first-page":"1","article-title":"What is the role of current mass spectrometry in pharmaceutical analysis?","author":"Khalikova","year":"2023","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.jpba.2024.116160_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0731-7085(99)00004-7","article-title":"Identification of losartan degradates in stressed tablets by LC-MS and LC-MS\/MS","volume":"20","author":"Zhao","year":"1999","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116160_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jpba.2019.05.022","article-title":"The contamination of valsartan and other sartans, part 1: New findings","author":"S\u00f6rgel","year":"2019","journal-title":"J. Pharm. Biomed. Anal..172"},{"key":"10.1016\/j.jpba.2024.116160_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpba.2019.04.035","article-title":"The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities","volume":"172","author":"Scherf-Clavel","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116160_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcoa.2021.100012","article-title":"Impurity profiling of bisoprolol fumarate by liquid chromatography-high-resolution mass spectrometry: A combination of targeted and untargeted approaches using a synthesis reaction matrix and general unknown comparative screening","volume":"1","author":"Wohlfart","year":"2021","journal-title":"J. Chromatogr. Open"},{"key":"10.1016\/j.jpba.2024.116160_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115955","article-title":"Application of advanced high resolution mass spectrometric techniques for the analysis of losartan potassium regarding known and unknown impurities","author":"Backer","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116160_bib27","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1021\/es5002105","article-title":"Identifying small molecules via high resolution mass spectrometry: communicating confidence","volume":"48","author":"Schymanski","year":"2014","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.jpba.2024.116160_bib28","unstructured":"Knowledge Database Edqm: Losartan potassium. https:\/\/extranet.edqm.eu\/4DLink1\/4DCGI\/Web_View\/mono\/2232. Accessed February 29, 2024."},{"key":"10.1016\/j.jpba.2024.116160_bib29","unstructured":"Amlodipine besilate European Pharmacopoeia 11.0, text number: 1491. Council of Europe, Strasbourg, France, 2022."},{"key":"10.1016\/j.jpba.2024.116160_bib30","unstructured":"Hydrochlorothiazide European Pharmacopoeia 11.0, text number 0394. Council of Europe, Strasbourg, France, 2022."},{"key":"10.1016\/j.jpba.2024.116160_bib31","article-title":"Inventors; Zhejiang Huahai Pharmaceuticals Co., assignee. Method for preparing high-purity losartan","author":"Yang","year":"2023","journal-title":"WO"},{"key":"10.1016\/j.jpba.2024.116160_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2022.107112","article-title":"Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties","volume":"147","author":"Sauge","year":"2022","journal-title":"Vasc. Pharm."},{"key":"10.1016\/j.jpba.2024.116160_bib33","first-page":"21","article-title":"Synthesis and spectral characterization of related compounds of Losartan potassium, an anti-hypertensive drug substance","volume":"7","author":"Lokamaheshwari","year":"2010","journal-title":"Org. Chem.: Indian J."},{"key":"10.1016\/j.jpba.2024.116160_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0731-7085(01)00556-8","article-title":"Photodegradation monitoring of amlodipine by derivative spectrophotometry","volume":"27","author":"Ragno","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116160_bib35","unstructured":"Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human. Report from the CMDh meeting held on 21-22 June 2022. (July 18, 2022). https:\/\/www.hma.eu\/fileadmin\/dateien\/Human_Medicines\/CMD_h_\/CMDh_pressreleases\/2022\/CMDh_press_release_-_June_2022_01.pdf. Accessed February 29, 2024."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524002000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524002000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:49:28Z","timestamp":1778507368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524002000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":35,"alternative-id":["S0731708524002000"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116160","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted and untargeted screening for impurities in losartan tablets marketed in Germany by means of liquid chromatography\/high resolution mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116160"}}